Læknablaðið - 01.04.2023, Blaðsíða 23

L ÆKNABL AÐIÐ 2023/109 191
Y F I R L I T S G R E I N
E N G L I S H S U M M A R Y
Autoimmune/inflammatory syndrome induced by aduvants
For decades, breast implants have been available for breast reconstructions and breast augmentations to
improve the patients’ health-related quality of life. Silicone implants (SI) have been used since the middle
of the last century for breast reconstruction, for example after breast cancer, for birth defects, gender
confirmation procedures, or for breast augmentation. Every year, several hundred SI are performed in Iceland
for these purposes, but no central register is maintained. It can be estimated that at least 1000 - 3000 women
have SI in Iceland and that around 300 Icelandic patients get SI every year.
This informal review article discusses the so-called ASIA syndrome, the immunological effects of silicone and
the possible relationship of SI to autoimmune diseases, symptoms, and diagnosis.
In the methodology, this paper does not rely on the strict conditions of systematic reviews, but the authors
relied only on peer-reviewed sources through PubMed, UpToDate and Scopus.
The keywords used are silicon, silicon implant, silicon particles, immune response, autoimmunity,
autoinflammation, Autoimmune/inflammatory syndrome induced by aduvants, ASIA, ASIA syndrome, breast
implant illness.
The paper reviews known facts about the disease, its characteristics, and statistical aspects.
doi 10.17992/lbl.2023.04.739
Sigurveig Þ. Sigurðardóttir1,2
Hannes Sigurjónsson3,4
Andri Már Þórarinsson4
Kristján Erlendsson1,5
1Department of Immunology, Landspitali
University Hospital, Reykjavik, 2University of
Iceland, Faculty of Medicine, 3Reykjavík Plastic
Surgery Clinic, 4Department of Reconstructive
Plastic Surgery, Landspítali National University
Hospital, 5Department of Internal Medicine,
Landspitali University Hospital
Correspondence: Sigurveig Þ. Sigurðardóttir,
veiga@landspitali.is
Key words: silicon, breast implant, ASIA
syndrome, autoinflammatory, autoimmunity.
1. Shoenfeld Y, Agmon-Levin N. 'ASIA' - Autoimmune/
inflammatory syndrome induced by adjuvants. J
Autoimmun 2011; 36: 4-8.
2. Colaris MJL, de Boer M, van der Hulst RR, et al. Two
hundreds cases of ASIA syndrome following silicone
implants: a comparative study of 30 years and a review
of current literature. Immunol Res 2017; 65: 120-8.
3. Hölmich LR, Friis S, Fryzek JP, et al. Incidence of sil-
icone breast implant rupture. Arch Surg 2003; 138: 801-6.
4. Cohen Tervaert JW, Colaris MJ, et al. Silicone breast
implants and autoimmune rheumatic diseases: Myth or
reality. Curr Opin Rheumatol 2017; 29: 348-54.
5. Watad A, Quaresma M, Bragazzi NL, et al. The
autoimmune/inflammatory syndrome induced by adju-
vants (ASIA)/Shoenfeld’s syndrome: descriptive analys-
is of 300 patients from the international ASIA syndrome
registry. Clin Rheumatol 2018; 37: 483-93.
6. O'Malley JT, Burgess BJ, Galler D, et al. Foreign body
response to silicone in cochlear implant electrodes in
the human. Otol Neurotol 2017; 38: 970-7.
7. Institute of Medicine Committee on the Safety of
Silicone Breast I. The National Academies Collection:
Reports funded by National Institutes of Health. In:
Bondurant S, Ernster V, Herdman R, editors. Safety of
Silicone Breast Implants. National Academies Press,
Washington 1999.
8. Balk EM, Earley A, Avendano EA, et al. Long-term
health outcomes in women with silicone gel breast
implants. Ann Intern Med 2016; 164: 164-75.
9. Watad A, Rosenberg V, Tiosano S, et al. Silicone breast
implants and the risk of autoimmune/rheumatic dis-
orders: A real-world analysis. Int J Epidemiol 2018; 47:
1846-54.
10. Coroneos CJ, Selber JC, Offodile AC, et al. US FDA
Breast Implant Postapproval Studies: Long-term
Outcomes in 99,993 Patients. Ann Surg 2019; 269: 30-6.
11. Watad A, Sharif K, Shoenfeld Y. The ASIA syndrome:
basic concepts. Mediterr J Rheumatol 2017; 28: 64-9.
12. Cohen Tervaert JW. Autoinflammatory/autoimmunity
syndrome induced by adjuvants (ASIA; Shoenfeld's
syndrome): A new flame. Autoimmun Rev 2018; 17:
1259-64.
13. Shoaib BO, Patten BM, Calkins DS. Adjuvant Breast
Disease: An Evaluation of 100 Symptomatic Women
with Breast Implants or Silicone Fluid Injections. Keio J
Med 1994; 43: 79-87.
14. Sène D. Small fiber neuropathy: Diagnosis, causes, and
treatment. Joint Bone Spine 2018; 85: 553-9.
15. Cawrse NH, Pickford MA. Cutaneous manifestation of
silicone dissemination from a PIP implant - a case for
prophylactic explantation? J Plast Reconstr Aesthetic
Surg 2011; 64: e208-e9.
16. Dijkman HBPM, Slaats I, Bult P. Assessment of Silicone
Particle Migration Among Women Undergoing
Removal or Revision of Silicone Breast Implants in the
Netherlands. JAMA Network Open 2021; 4: e2125381-e.
17. Errico V, Perroni G, Milana F, et al. Internal mammary
lymph node siliconoma in absence of prosthesis rupt-
ure: a case series that raises concern for potential risk of
overdiagnosis. Gland Surg 2021; 10: 2123-9.
18. Dragu A, Theegarten D, Bach AD, et al. Intrapulmonary
and cutaneous siliconomas after silent silicone breast
implant failure. Breast J 2009; 15: 496-9.
19. Chung L, Maestas D, Lebid A, et al. Interleukin-17 and
senescence regulate the foreign body response. bioRxiv;
2019.
20. Wolfram D, Rabensteiner E, Grundtman C, et al. T
regulatory cells and TH17 cells in peri–silicone implant
capsular fibrosis. Plast Reconstr Surg 2012; 129:
327e-337e.
21. Liangjiao C, Yiyuan K, Hongbing G, et al. The current
understanding of immunotoxicity induced by silica
nanoparticles. Nanomedicine 2019; 14: 1227-9.
22. Chen L, Liu J, Zhang Y, et al. The toxicity of silica nano-
particles to the immune system. Nanomedicine 2018;
13: 1939-62.
23. Schaefer CJ, Wooley PH. The influence of silicone
implantation on murine lupus in MRL lpr/lpr mice. J
Rheumatol 1999; 26: 2215-21.
24. Maijers MC, de Blok CJM, Niessen FB, et al. Women
with silicone breast implants and unexplained systemic
symptoms: A descriptive cohort study. Neth J Med
2014; 71: 534-40.
25. Goren I, Segal G, Shoenfeld Y. Autoimmune/
inflammatory syndrome induced by adjuvant (ASIA)
evolution after silicone implants. Who is at risk? Clin
Rheumatol 2015; 34: 1661-6.
26. Bizjak M, Selmi C, Praprotnik S, et al. Silicone implants
and lymphoma: The role of inflammation. J Autoimmun
2015; 65: 64-73.
27. Lajevardi SS, Rastogi P, Isacson D, et al. What are the
likely causes of breast implant associated anaplastic
large cell lymphoma (BIA-ALCL)? JPRAS Open 2022;
32: 34-42.
28. Doloff JC, Veiseh O, de Mezerville R, et al. The surface
topography of silicone breast implants mediates the
foreign body response in mice, rabbits and humans.
Nature Biomed Engineer 2021; 5: 1115-30.
29. Steinke K, Brook P, Ramuz O. Radiological pitfall:
Siliconoma in internal mammary lymph node mimics
breast cancer recurrence. Radiol Case Rep 2011; 6: 601.
30. Juanpere S, Perez E, Huc O, et al. Imaging of breast
implants-a pictorial review. Insights Imaging 2011; 2:
653-70.
31. Cohen Tervaert JW, Mohazab N, Redmond D, et
al. Breast implant illness: scientific evidence of its
existence. Expert Rev Clin Immunol 2022; 18: 15-29.
32. Colaris MJL, van der Hulst RR, Tervaert JWC. Vitamin
D deficiency as a risk factor for the development of
autoantibodies in patients with ASIA and silicone
breast implants: a cohort study and review of the litera-
ture. Clin Rheumatol 2017; 36: 981-93.
33. Brawer AE. Amelioration of systemic disease after
removal of silicone gel-filled breast implants. J Nutr
Environm Med 2000; 10: 125-32.
34. Gabriel SE, O'Fallon WM, Kurland LT, et al. Risk of
connective-tissue diseases and other disorders after
breast implantation. N Engl J Med 1994; 330: 1697-702.
35. Sánchez-Guerrero J, Colditz GA, Karlson EW, et al.
Silicone breast implants and the risk of connective-tis-
sue diseases and symptoms. N Engl J Med 1995; 332:
1666-70.
36. Hennekens CH, Lee I-M, Cook NR, et al. Self-reported
breast implants and connective-tissue diseases in
female health professionals: a retrospective cohort
study. JAMA 1996; 275: 616-21.
37. Janowsky EC, Kupper LL, Hulka BS. Meta-Analyses of
the Relation between Silicone Breast Implants and the
Risk of Connective-Tissue Diseases. N Engl J Med 2000;
342: 781-90.
38. Statement from FDA Principal Deputy Commissioner
Amy Abernethy M:D., Ph.D. and Jeff Shuren, M.D.,
J.D., director of the FDA‘s Center for Devices and
Radiological Health on FDA‘s new efforts to protect
women‘s health and help to ensure the safety of breast
implants. 2019. fda.gov/news-events/press-announcem-
ents/statement-fda-principal-deputy-commissioner-
amy-abernethy-md-phd-and-jeff-shuren-md-jd-
director-fdas - janúar 2023.
39. Kassem S, Watad A, Bragazzi NL, et al. On chronic
fatigue syndrome and nosological categories. Clin
Rheumatol 2018; 37: 1161-70.
40. Dotan A, David P, Arnheim D, et al. The autonomic
aspects of the post-COVID19 syndrome. Autoimm Rev
2022; 21: 103071.
41. Wallukat G, Hohberger B, Wenzel K, et al. Functional
autoantibodies against G-protein coupled receptors in
patients with persistent Long-COVID-19 symptoms. J
Transl Autoimmun 2021; 4: 100100.
42. Macedo GE, de Brum Vieira P, Rodrigues NR, et al.
Fungal compound 1-octen-3-ol induces mitochondrial
morphological alterations and respiration dysfunctions
in Drosophila melanogaster. Ecotoxicol Environ Saf
2020; 206: 111232.
43. Shoenfeld Y, Ryabkova VA, Scheibenbogen C, et al.
Complex syndromes of chronic pain, fatigue and cogn-
itive impairment linked to autoimmune dysautonomia
and small fiber neuropathy. Clin Immunol 2020; 214:
108384.
44. Halpert G, Watad A, Tsur AM, et al. Autoimmune
dysautonomia in women with silicone breast implants.
J Autoimmun 2021; 120: 102631.
Heimildir